Compare Stocks → Move Your Money Before May 22 (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BMEANASDAQ:BYSINASDAQ:FIXXNASDAQ:VERANASDAQ:XOMA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$10.78+3.0%$14.72$8.13▼$43.69$386.89M-0.53981,455 shs583,151 shsBYSIBeyondSpring$2.13-6.2%$2.42$0.65▼$4.00$82.90M0.15183,355 shs33,673 shsFIXXHomology Medicines$0.52$0.46▼$1.48$54.33M-0.1390,307 shs401,400 shsVERAVera Therapeutics$39.65+2.5%$43.12$6.07▼$50.78$2.16B1.051.28 million shs827,925 shsXOMAXOMA$25.41+0.2%$24.86$13.48▼$27.00$295.77M0.5820,669 shs6,127 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion-2.79%-6.18%-29.97%-36.51%-66.26%BYSIBeyondSpring-6.58%+26.11%-37.12%+149.40%+134.36%FIXXHomology Medicines0.00%0.00%0.00%+168.59%+95.28%VERAVera Therapeutics-3.15%-2.00%-6.95%+28.20%+510.25%XOMAXOMA-1.09%+3.13%+9.55%+25.61%+32.08%Move Your Money Before May 22 (Ad)The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMEABiomea Fusion1.0351 of 5 stars3.40.00.00.00.03.30.6BYSIBeyondSpring0.0024 of 5 stars0.00.00.00.00.02.50.0FIXXHomology Medicines2.295 of 5 stars3.30.00.04.80.00.80.6VERAVera Therapeutics0.7778 of 5 stars1.52.00.00.02.05.00.0XOMAXOMA3.5097 of 5 stars3.51.00.03.02.51.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMEABiomea Fusion2.75Moderate Buy$53.13392.81% UpsideBYSIBeyondSpringN/AN/A$1.25-41.31% DownsideFIXXHomology Medicines2.50Moderate Buy$0.75∞ UpsideVERAVera Therapeutics3.00Buy$32.29-18.57% DownsideXOMAXOMA3.00Buy$74.00191.22% UpsideCurrent Analyst RatingsLatest BYSI, BMEA, XOMA, FIXX, and VERA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2024XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$74.004/5/2024VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$56.004/3/2024BMEABiomea FusionOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$70.004/2/2024BMEABiomea FusionJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$51.00 ➝ $14.004/1/2024BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.004/1/2024BMEABiomea FusionTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.003/27/2024VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $56.003/21/2024VERAVera TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$21.00 ➝ $34.003/6/2024BMEABiomea FusionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.002/16/2024XOMAXOMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$74.002/6/2024BMEABiomea FusionTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$55.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMEABiomea FusionN/AN/AN/AN/A$4.74 per shareN/ABYSIBeyondSpring$1.35M61.41N/AN/A($0.36) per share-5.92FIXXHomology Medicines$1.16M0.00N/AN/A$1.26 per share0.00VERAVera TherapeuticsN/AN/AN/AN/A$1.94 per shareN/AXOMAXOMA$4.76M62.14N/AN/A$7.72 per share3.29Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMEABiomea Fusion-$117.25M-$3.46N/AN/AN/AN/A-69.35%-59.65%5/7/2024 (Estimated)BYSIBeyondSpring-$33.28MN/A0.00∞N/AN/AN/AN/AN/AFIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%5/9/2024 (Estimated)VERAVera Therapeutics-$95.99M-$2.29N/AN/AN/AN/A-73.33%-50.79%5/9/2024 (Estimated)XOMAXOMA-$40.83M-$4.04N/AN/AN/A-886.91%-25.17%-17.08%5/14/2024 (Estimated)Latest BYSI, BMEA, XOMA, FIXX, and VERA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023BMEABiomea FusionN/A-$0.98-$0.98-$0.98N/AN/A3/20/2024Q4 2023VERAVera Therapeutics-$0.53-$0.58-$0.05-$0.58N/AN/A3/8/2024Q4 2023XOMAXOMA-$0.36-$0.49-$0.13$0.89$1.01 million$1.83 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMEABiomea FusionN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/AFIXXHomology MedicinesN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/AXOMAXOMAN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMEABiomea FusionN/A7.847.84BYSIBeyondSpringN/AN/AN/AFIXXHomology MedicinesN/A7.257.25VERAVera Therapeutics0.497.717.71XOMAXOMA1.348.688.68OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMEABiomea Fusion96.72%BYSIBeyondSpring40.29%FIXXHomology Medicines31.32%VERAVera Therapeutics99.21%XOMAXOMA95.92%Insider OwnershipCompanyInsider OwnershipBMEABiomea Fusion26.27%BYSIBeyondSpring29.31%FIXXHomology Medicines16.10%VERAVera Therapeutics21.70%XOMAXOMA7.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBMEABiomea Fusion10335.89 million26.46 millionOptionableBYSIBeyondSpring7338.92 million27.52 millionOptionableFIXXHomology Medicines758.13 million48.77 millionOptionableVERAVera Therapeutics5154.45 million42.64 millionOptionableXOMAXOMA1311.64 million10.80 millionOptionableBYSI, BMEA, XOMA, FIXX, and VERA HeadlinesSourceHeadlineXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)finance.yahoo.com - April 25 at 8:40 AMXOMA's (XOMA) Buy Rating Reiterated at HC Wainwrightmarketbeat.com - April 25 at 8:09 AMXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)globenewswire.com - April 25 at 7:30 AMXOMA (NASDAQ:XOMA) Share Price Crosses Above 200-Day Moving Average of $20.30americanbankingnews.com - April 25 at 3:14 AMActym Therapeutics Appoints Thomas Smart as CEOprnewswire.com - April 24 at 9:00 AMXOMA (NASDAQ:XOMA) shareholders have earned a 16% CAGR over the last five yearsfinance.yahoo.com - April 20 at 9:43 AMXOMA (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average of $19.93americanbankingnews.com - April 17 at 2:58 AMXOMA Co. (NASDAQ:XOMA) Shares Sold by Stonepine Capital Management LLCmarketbeat.com - April 9 at 9:43 PMXOMA Corporation Announces Closing of Tender Offerglobenewswire.com - April 3 at 9:00 AMXOMA Declares Quarterly Preferred Stock Dividendsglobenewswire.com - March 21 at 7:30 AMXOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.globenewswire.com - March 19 at 4:05 PMKINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEbusinesswire.com - March 13 at 11:49 AMXOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 8 at 1:03 PMXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Valuefinance.yahoo.com - March 8 at 7:51 AMXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Valueglobenewswire.com - March 8 at 7:30 AMXOMA to Present at Upcoming Investor Conferences in Marchglobenewswire.com - February 28 at 7:30 AMKINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEbusinesswire.com - February 19 at 11:03 AMCompare with Maple Leaf Green World Inc (4HV0)msn.com - February 18 at 12:30 PMXOMA to acquire Kinnate Biopharmathepharmaletter.com - February 17 at 10:21 AMXOMA Mar 2024 20.000 putfinance.yahoo.com - February 17 at 10:21 AMXOMA Jun 2024 25.000 callfinance.yahoo.com - February 17 at 10:21 AMBiotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharmabenzinga.com - February 16 at 1:37 PMXOMA Agrees to Acquire Kinnate Biopharmamarketwatch.com - February 16 at 8:36 AMXOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Rightfinance.yahoo.com - February 16 at 8:36 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBiomea FusionNASDAQ:BMEABiomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.BeyondSpringNASDAQ:BYSIBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.Homology MedicinesNASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.Vera TherapeuticsNASDAQ:VERAVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.XOMANASDAQ:XOMAXOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.